

**Declaration form on Nothing to Declare or Nothing New to Declare for use in the information exchange**

Measure	Nothing to declare	Nothing new to declare	Year of last declaration if nothing new to declare
A, part 1	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (i)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (ii)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (iii)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
B	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
C	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
E	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
F	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox" value="1992"/>
G	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox" value="2011"/>

(Please mark the appropriate box(es) for each measure with a tick, and fill in the year of last declaration in the last column where applicable.)

Date: **March, 2014**

State Party to the Convention: **Czech Republic**

Date of ratification/accession to the Convention:

30 April 1973 (former Czechoslovakia), **24 March 1993** (Czech Republic)

National point of contact: **Michal Merxbauer, Ph.D.**

Director

Department of Non-Proliferation

State Office for Nuclear Safety

Senovazne nam. 9

110 00 Praha 1

**Form A, part 1 (i)**

*Exchange of data on research centres and laboratories<sup>1</sup>*

1. Name(s) of facility<sup>2</sup>

Military Health Institute, Biological Defence Department at Techonin

*Note: declared anew because of transformation of military health service and change in organisational structure of Ministry of Defence*

2. Responsible public or private organization or company

Military Health Institute (Ministry of Defence, Military Medical Agency)

3. Location and postal address

561 66 Techonin, Czech Republic

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

Fully financed by the Ministry of Defence

5. Number of maximum containment units<sup>3</sup> within the research centre and/or laboratory, with an indication of their respective size (m<sup>2</sup>)

1 unit BSL4; total area 50 m<sup>2</sup>

6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

Cultivation of microbe (*Francisella tularensis*, vaccine strain LVS) for immunological studies, preparation of monoclonal antibodies and PCR probes.  
cDNA and synthetic sequences of viral hemorrhagic fevers (Marburg, Machupo, Junin, Congo-Crimean, Lassa, Ebola, Sabia)

---

<sup>1</sup> The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.

<sup>2</sup> For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".

<sup>3</sup> In accordance with the latest edition of the WHO Laboratory Biosafety Manual, or equivalent.

**Form A, part 1 (i)**

*Exchange of data on research centres and laboratories*

1. Name(s) of facility

National Institute for Nuclear, Chemical and Biological Protection, Department of Biological Protection, Laboratory for Biological Monitoring and Protection

2. Responsible public or private organization or company

National Institute for Nuclear, Chemical and Biological Protection,

3. Location and postal address

Kamenná 71, 262 31 Milín, Czech Republic

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

National Institute for Nuclear, Chemical and Biological Protection is a public research institution. It is partly financed by own resources and partly financed by state budget.

5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m<sup>2</sup>)

2 units BSL4; area of each unit 14,2 m<sup>2</sup> (total area 28,4 m<sup>2</sup>)

6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

Development, testing and evaluation of detection, and identification methods (microbiological cultivation, methods of molecular biology, advanced mass spectrometry).

Integrated Rescue System uses this laboratory in case of alleged bioterrorism (primary assessment and investigation of suspicious packages – primary detection and identification, etc.)

bacteria: *Bacillus anthracis*, *Yersinia pestis*, *Francisella tularensis*, *Brucella species*, *Salmonella typhi*, *Burkholderia mallei*, *Burkholderia pseudomallei*, *Chlamydia psitaci*, *Coxiella burnetii*, *Vibrio cholerae*, *Clostridium botulinum*;

bacterial simulans: *Geobacillus stearothermophilus*

viruses: Yellow Fever virus, virus Dengue and extracts of RNA viruses (virus Marburg, virus Ebola, virus Hantaan, Lassa fever virus, virus Junin, Congo-Crimean haemorrhagic fever virus, virus Machupo, virus Junin)

toxins: trichothecene toxins, aflatoxins, microcystin,

### **National biological defence research and development programmes Declaration**

Are there any national programmes to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such programmes would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

**No**

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of each programme.

Form A, part 2 (ii)

### **National biological defence research and development programme**

#### **Description**

1. State the objectives and funding of the programme and summarize the principal research and development activities conducted in the programme.


*There was no programme of national biological defence research during 2013 and the R&D activities of the national defence research programmes were not aimed at area covered by the BWC. They included e.g. biological detection of toxic substances in water, equipment of mobile diagnostic CBRN teams for sampling and sample transport or decontamination.*

*To enhance security of the Czech Republic and its citizens Ministry of Interior finances another type of research - security research. Security research uses applied research, experimental development and innovations in the area of identification, prevention and protection against unlawful actions towards citizens of the Czech Republic, its organizations and structures, possessions and infrastructure as well as against natural or industrial disasters.*

2. State the total funding for the programme and its source.
3. Are aspects of this programme conducted under contract with industry, academic institutions, or in other non-defence facilities?  
Yes / No
4. If yes, what proportion of the total funds for the programme is expended in these contracted or other facilities?
5. Summarize the objectives and research areas of the programme performed by contractors and in other facilities with the funds identified under paragraph 4.

6. Provide a diagram of the organizational structure of the programme and the reporting relationships (include individual facilities participating in the programme).

*Because of transformation of military health service and change in organisational structure of Ministry of Defence we provide revised diagram.*



7. Provide a declaration in accordance with Form A, part 2 (iii) for each facility, both governmental and non-governmental, which has a substantial proportion of its resources devoted to the national biological defence research and development programme, within the territory of the reporting State, or under its jurisdiction or control anywhere.

*Forms A, part 2 (iii) are not attached, because there was no programme of national biological defence research during 2013 as mentioned above under #1.*

**Encouragement of publication of results and promotion of use of knowledge**

Keough D. T. , Hockova D., Rejman D., Spacek P., Vrbkova S., Krecmerova M., Eng W. S., Jans H., West N. P., Naesens L. M. J., de Jersey J., Guddat L. W.: Inhibition of the Escherichia coli 6-Oxopurine Phosphoribosyltransferases by Nucleoside Phosphonates: Potential for New Antibacterial Agents. *J. Med. Chem.*, 2013, 56 (17), pp 6967–6984

Vaclavikova M., Malachova A., Veprikova Z., Dzuman Z., Zachariasova M., Hajslova J.: Emerging mycotoxins in cereals processing chains: changes of enniatins during beer and bread making. *Food Chem.* 2013 Jan 15;136(2), pp 750-757

Ostry V., Malir F., Ruprich J.: Producers and important dietary sources of ochratoxin A and citrinin. *Toxins*, 2013, 5, 1574-1586.

Skarkova J., Ostry V., Malir F., Roubal T.: Determination of Ochratoxin A in Food by High Performance Liquid Chromatography. *Analytical Letters*, 2013, 46, 10, 1495-1504.

Malir F., Ostry V., Novotna E.: Toxicity of the mycotoxin ochratoxin A (OTA) in the light of recent data. *Toxin Review*, 2013, 32, 2, 19-33.

Malir F., Ostry V., Dofkova M., Roubal T., Dvorak V., Dohnal V.: Ochratoxin A levels in blood serum of Czech women in the first trimester of pregnancy and its correspondence with dietary intake of the mycotoxin contaminant. *Biomarkers*, 2013, 18, 8, 673-678.

Dohnal V., Dvorak V., Malir F., Ostry V., Roubal T.: A comparison of ELISA and HPLC methods for determination of ochratoxin A in human blood serum in the Czech Republic., *Food and Chemical Toxicology*, 2013, 62, 427–431

Malir F., Ostry V., Pfohl-Leszkowicz A., Novotna E.: Mycotoxin ochratoxin A and developmental and reproductive toxicity - an overview. *Birth Defects Research Part B: Developmental and Reproductive Toxicology*, 2013, 98, 493-502.

## Form E

### Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulations	Other measures <sup>4</sup>	Amended since last year
Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	<b>Yes</b>	<b>Yes</b>	<b>No</b>	<b>Yes*</b>
Exports of micro-organisms <sup>5</sup> and toxins	<b>Yes</b>	<b>Yes</b>	<b>No</b>	<b>No</b>
Imports of micro-organisms <sup>5</sup> and toxins	<b>Yes</b>	<b>Yes</b>	<b>No</b>	<b>No</b>
Biosafety <sup>6</sup> and biosecurity <sup>7</sup>	<b>Yes (partly)</b>	<b>Yes (partly)</b>	<b>No</b>	<b>No</b>

\*During 2013 was amended Decree No. 474/2002 Coll., implementing the Act No. 281/2002 Coll., on Some Measures Related to a Ban on Bacteriological (Biological) and Toxin Weapons. There were amended especially lists of agents and toxins.

---

<sup>4</sup> Including guidelines.

<sup>5</sup> Micro-organisms pathogenic to man, animals and plants in accordance with the Convention.

<sup>6</sup> In accordance with the latest version of the WHO Laboratory Biosafety Manual or equivalent national or international guidance.

<sup>7</sup> In accordance with the latest version of the WHO Laboratory Biosecurity Guidance or equivalent national or international guidance.